<DOC>
	<DOC>NCT02247375</DOC>
	<brief_summary>Safety, pharmacokinetics, pharmacodynamics [CD11b/CD18 (Mac-1) expression] and efficacy.</brief_summary>
	<brief_title>Pharmacokinetics, Safety and Efficacy of BIIL 284 BS in Patients With Rheumatoid Arthritis (RA)</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<criteria>Male and female from 18 to 65 years of age Patients suffering from active rheumatoid arthritis as defined by the ARA criteria revised 1987 At least 4 of the following 7 criteria must have been present: morning stiffness in and around the joints lasting at least 1 hour before maximal improvement for at least 6 weeks arthritis (soft tissue thickening or fluid not bony overgrowth alone) of at least 3 joint areas for at least 6 weeks arthritis of hand joints (at least one area swollen in a wrist, metacarpophalangeal (MCP) or proximal interphalangeal (PIP) joint) for at least 6 weeks symmetric arthritis (observed by a physician) with simultaneous involvement of the joints on both sides of the body for at least 6 weeks rheumatoid nodules (observed by a physician) over bony prominences or extensor surfaces or in juxtaarticular regions serum rheumatoid factor positive xray changes typical of rheumatoid arthritis (erosions or unequivocal bony decalcification localised in or most marked adjacent to the involved joints) Patient belonging to the RA functional class I, II or III Patient's written informed consent Pregnancy (to be excluded by pregnancy test) or breast feeding Women of childbearing potential not using adequate contraception Treatment with methotrexate in the previous month or intended use during the trial period Treatment with slow acting antirheumatic drugs (SAARDs)/diseasemodifying antirheumatic drugs (DMARDs) other than parenteral gold, Dpenicillamine, sulfasalazine, chloroquine / hydroxychloroquine corticosteroid during the last 2 months prior to study entry Treatment with more than one SAARD/DMARD and/or corticosteroid during the last 2 months prior to study entry Change in treatment with SAARDs/DMARDs during the last 2 months prior to study entry or intended change during the trial duration Change in treatment with corticosteroids during the last month prior to study entry or intended change during the trial duration Systemic treatment with corticosteroids at a dose higher than 10 mg/day or 0.2 mg/kg/day (prednisone equivalent), respectively (whichever is lower) during the last month prior to study entry or their intended use during the trial treatment period Change in treatment with nonsteroidal antiinflammatory drugs (NSAIDs) during the last month prior to study entry or intended change during the trial duration Treatment with EnbrelTM (etanercept) or experimental therapies during the last 3 months prior to study entry Synovectomy and/or surgical treatment for RA in the previous month or during the trial Clinical evidence of known severe cardiovascular, hepatic, renal, respiratory, metabolic, haematological, immunological, gastrointestinal, hormonal or mental disorders Any other rheumatological or nonrheumatological disease that could interfere with the evaluation of efficacy and safety Patients with active malignant disease Patients with chronic or acute infections during the previous month Patients with abnormal, clinically relevant laboratory values not related to RA Participation in another clinical trial during this study or during the previous month Previous participation in this trial (i.e. having been allocated a randomized treatment number) Patient unable to comply with the protocol Patient with known drug abuse Patient with known alcohol abuse</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>